Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending December 31, 2021

Company Overview

Ensysce Biosciences, Inc. is a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the fear of and the potential for opioid misuse, abuse and overdose. Our current development pipeline includes two new drug platforms - an abuse-resistant prodrug technology – the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection prodrug technology - the Multi-Pill Abuse Resistant, or the MPAR™ platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR™ platform when combined with our TAAP prodrugs is designed not only to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat is an ingredient in our overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Stock Snapshot

IR Contacts

Company

Ensysce Biosciences, Inc.
7946 Ivanhoe Ave
Suite 201
La Jolla, CA 92037
T: 858-263-4196
info@ensysce.com

Investor Relations

MZ North America
5055 Avenida Encinas
Suite 130
Carlsbad, CA 92008
T: 203-741-8811


Shannon Devine
shannon@mzgroup.us

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.